- POSITIVE
Annual Revenue Corona Remedies Mar-2026 Annual Revenue is Rs 1,414 Cr which is growth of 17.6% YoY.
- POSITIVE
Annual Net Profit Corona Remedies Mar-2026 Annual Net Profit is Rs 185 Cr which is growth of 24.0% YoY.
Corona Remedies was incorporated on August 27, 2004. The company is an India-focused branded pharmaceutical firm involved in developing, manufacturing, and marketing formulations across women’s health, cardio-diabetes, pain, urology, and other therapies
| Bidding Dates |
|---|
| 08 Dec 2025 - 10 Dec 2025 |
| Subscription |
|---|
| 137.04x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,112 | 1 | 13 | 14 | 6.2 M | ₹1008 - ₹1062 | 69 % | ₹6,220.5 M - ₹6,553.7 M | RHP DOC |
Corona Remedies IPO SUBSCRIPTION STATUS
10 Dec '25Total137.04x
Retail Individual Investor28.73x
HNI (NII) Investors208.88x
Qualified Institutional Buyers278.52x
Employees14.72x
Corona Remedies IPO overall subscription rate was 137.04 times the total available shares
Corona Remedies IPO retail subscription rate was 28.73 times in the retail segment
Corona Remedies IPO non-institutional investor subscription rate was 208.88 times in the non-institutional investor category
Corona Remedies IPO Qualified Institutional Bidder subscription rate was 278.52 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers | Employees |
|---|---|---|---|---|
| Category Reservation | 35% | 15% | 50% | 0.94% |
10 Dec 2025 (Day 3) | 28.73x | 208.88x | 278.52x | 14.72x |
09 Dec 2025 (Day 2) | 6.37x | 26.8x | 1.67x | 4.03x |
08 Dec 2025 (Day 1) | 0.87x | 0.79x | - | 1.35x |
Corona Remedies FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| Q1FY26 | 346.5 | 46.2 | 25.4 | 12.9 | 20.7% |
| FY25 | 1,196.4 | 149.4 | 190.5 | 99.5 | 20.6% |
| FY24 | 1,014.5 | 90.5 | 156.8 | -129.0 | 15.9% |
| FY23 | 884.1 | 84.9 | 102.7 | 8.9 | 15.3% |
Corona Remedies IPO SUBSCRIPTION STATUS DETAILS
Corona Remedies had 6.2 M shares on offer
Corona Remedies IPO offer price was in the range ₹1008 - ₹1062
Corona Remedies IPO minimum Investment was ₹14112
Corona Remedies IPO issue size was ₹ 6,220.5 M - ₹ 6,553.7 M
Corona Remedies had a minimum lot size of 14 Shares per application
Corona Remedies NUMBER OF SHARES ON OFFER
Total6.2 M
Fresh Issue0
Offer for Sale6.2 M
Post Issue Promoter Holding %69 %
Corona Remedies IPO IMPORTANT DATES
| Issue Open Date | 08 Dec 2025 |
| Issue close Date | 10 Dec 2025 |
| Allotment Date | 11 Dec 2025 |
| Refund Date | 12 Dec 2025 |
| Demat Account Credit Date | 12 Dec 2025 |
| Listing Date | 15 Dec 2025 |
| Listing on Exchange(s) | NSE and BSE |
| Corona Remedies Allotment Status | Exchange/ Registrar |
Corona Remedies IPO subscription opened on 08 Dec 2025, and closed on 10 Dec 2025
IPO allotment for Corona Remedies was finalized on Thursday, 11 Dec 2025
IPO listing for Corona Remedies was on NSE and BSE on Monday, 15 Dec 2025
Corona Remedies IPO LISTING GAINS
| Issue Price (adjusted) | 1062.0 |
| Listing Open Price | 1470.0 |
| Listing Close Price | 1438.4 |
| Listing Gain% | 38.4% |
| Current Gain% | 102.4% |
Corona Remedies Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corona Remedies Ltd. | 2149.6 | 13147 | 63.5 | 3.5 | 8.4 | 24.8 | 15.4 | 1413.8 | 17.6 | 185.1 | 23.9 | 33.8 | 18.3 |
| Sun Pharmaceutical Industries Ltd. | 1777.7 | 426529.8 | 38.9 | 7.9 | 6.9 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 45.7 | 4.9 |
| Divi's Laboratories Ltd. | 9780 | 259628.3 | 88.8 | 3.3 | 23.1 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4613.4 | 175478.9 | 82.6 | -110.5 | 10.1 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 55.8 | -0.7 |
| Laurus Labs Ltd. | 2405.5 | 129972.1 | 97 | 1 | 16.6 | 16.8 | 8.4 | 6861.3 | 22.2 | 888.8 | 148 | 24.8 | 95.9 |
| Zydus Lifesciences Ltd. | 1245.5 | 125326.4 | 27.8 | -17.9 | 4.4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Corona Remedies annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
17.6%
2Y CAGR
17.7%
Net Profit Ann.
1Y CHG
24%
2Y CAGR
42.9%
Operating Exp. Ann.
1Y CHG
16%
2Y CAGR
13.6%
Corona Remedies INFORMATION ON IPO ISSUE
About Corona Remedies
Corona Remedies was incorporated on August 27, 2004. The company is an India-focused branded pharmaceutical firm involved in developing, manufacturing, and marketing formulations across women’s health, cardio-diabetes, pain, urology, and other therapies
Object of the Issue
- To achieve the benefits of listing the equity shares on the stock exchanges
- For the offer for sale of equity shares of face value of Rs 10 each aggregating up to Rs 8,000.00 million
Corona Remedies - PROMOTERS
| Name |
|---|
| Kirtikumar Laxmidas Mehta |
| Niravkumar Kirtikumar Mehta |
| Ankur Kirtikumar Mehta |
Corona Remedies - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Kirtikumar Laxmidas Mehta | Chairman & Non-Executive Director |
| Niravkumar Kirtikumar Mehta | Managing Director & Chief Executive Officer |
| Ankur Kirtikumar Mehta | Joint Managing Director |
| Viral Bhupendrabhai Sitwala | Whole-Time Director |
| Ameetkumar Hiranyakumar Desai | Independent Director |
| Monica Hemal Kanuga | Independent Director |
| Shirish Gundopant Belapure | Independent Director |
| Bhaskar Vemban Iyer | Independent Director |
Corona Remedies Book Running Lead Manager
JM Financial Limited
corona.ipo@jmfl.com
IIFL Capital Services Limited
corona.ipo@iiflcap.com
Kotak Mahindra Capital Company Limited
coronaremedies.ipo@kotak.com
Corona Remedies Registrar to the Offer
Bigshare Services Private Limited
ipo@bigshareonline.com
Corona Remedies Strengths
Diversified product portfolio
The company has a diversified portfolio of 67 brands (as of December 31, 2024), with key focus areas—women’s healthcare, cardio-diabetes, pain management, and urology—contributing 67.4% of domestic sales, growing at a 24.37% CAGR over three years
Strength
Pan-India presence
The company’s focus on specialist doctors and strategic presence in urban and semi-urban areas has enabled it to outpace overall IPM prescription growth from MAT December 2021 to 2024, targeting the high-potential “middle of the pyramid” segment
Strength
Corona Remedies Risks
Dependent on third party vendors
The company relies on third-party suppliers, without long-term contracts, for raw materials, accounting for over 25% of total expenses. It also depends on its group company, La Chandra Pharmalab, for key APIs in women’s healthcare, which may affect supply continuity
Risk
Dependent on manufacturing plants
The company’s operations depend on effectively managing its manufacturing and R&D facilities, which face risks like equipment failure, accidents, power or water disruptions, and external factors such as natural disasters or regulatory delays
Risk
Regulations & quality standards
The company must comply with quality and regulatory standards set by various Indian and international authorities, including the Ministry of Health, the Ministry of Ayush, the Ministry of Environment, and other relevant agencies
Risk
IPO FAQs
This IPO consists of an offer for sale of up to Rs 655.4 crore, of 6,171,101 shares.
The promoters of the company are Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 1008.0 - 1062.0.
The IPO application opens on Dec 08, 2025 and closes on Dec 10, 2025.
The minimum lot size for the IPO is 14. The maximum lot size for the IPO is 182.
For all category investors, the minimum application amount for this IPO is Rs. 14,112.0, the maximum value for this IPO is Rs 193,284.0.
This IPO will be allotted on Dec 11, 2025.
The refund will be credited to your account on Dec 12, 2025.
The allotted shares will be credited to your demat on Dec 12, 2025.
Corona Remedies Ltd.’s shares listed on the stock exchanges on Dec 15, 2025.